Monthly Archives: December 2022

Takeda Acquires Nimbus’ Tyk2 Autoimmune Program
December 13, 2022

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset in the significant new therapeutic category of selective Tyk2

Leave a comment

What Took So Long: How Tech Has Finally Caught Up With Transcription Factors
December 6, 2022

By Gerry Harriman and Jonathan Montagu, CSO and CEO, respectively, and co-founders of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. HotSpot Therapeutics today announced a strategic collaboration with Abbvie to develop IRF5 transcription factor inhibitors

Leave a comment